Alnylam Pharmaceuticals
Last updated Jun 21, 2026
Evidence Sources
2
Competitive Findings
0
Portfolio Developments
0
Regulatory Precedents
5
Clinical Programs
0
Confidence Coverage
72%
Audit
- Competitor findings: 0
- Portfolio developments: 0
- Self-competition findings removed: 0
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Oncology
- Hepatocellular Carcinoma
Highest priority development: October - December 2024 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
Regulatory precedent
Why this matters: sets a safety guidance precedent in the same sub-indication (liver cancer) as Alnylam Pharmaceuticals.
Competitive pressure: Low
Portfolio impact: Low
Evidence coverage: 72%
Active Signals
1
Investigate Priority
0
Opportunity Score
16
Buyer Quality
6 · Emerging
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJun 21, 2026Score 16Alnylam's ALN-BCAT Study in Hepatocellular Carcinoma Evaluates Safety and Efficacy
Oncology · Hepatocellular Carcinoma
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
No portfolio development items are linked to this company yet.
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- October - December 2024 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)Moderate Confidence · 72%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - S6 (R1) Addendum: Preclinical Safety Evaluation of Biotechnology - Derived PharmaceuticalsModerate Confidence · 72%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)Moderate Confidence · 72%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and DeathModerate Confidence · 72%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
No clinical developments are linked yet.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
No investigate-priority signals are active for this company.
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Alnylam Pharmaceuticals right now?
- Which regulatory precedents should Alnylam Pharmaceuticals monitor in Oncology and Hepatocellular Carcinoma?
- Which pipeline programs should Alnylam Pharmaceuticals prioritize for competitive review?
- What signals require immediate investigation for Alnylam Pharmaceuticals?
- Summarize the strategic implications of recent developments for Alnylam Pharmaceuticals.
- Where is the greatest uncertainty in Alnylam Pharmaceuticals's competitive positioning?